Patrys CEO and MD, Dr James Campbell, has been interviewed by the drug development experts Beacon Intelligence about the Company’s path to the clinic.
Here’s an excerpt of what he had to say:
“Patrys’ deoxymab antibodies are the only antibodies that show single agent synthetic lethality. In multiple models we’ve shown reduction of cancer load in DDR deficient cancer cell lines, but this is lost in the matching DDR proficient comparator lines. This positions deoxymabs well for cancers such as Triple-Negative Breast Cancer (TNBC), and other cancers on both sides of the blood brain barrier with significant rates of DDR mutations.”